Vladimir Razinkov, PhD, Advisor
I have over 25 years of experience in analytical, drug product and formulation development of pharmaceutical and biopharmaceutical products. An innovator with 70+ peer-reviewed publications.
Samdolite Pharmaceuticals Inc. is a pre-clinical–stage biotechnology company developing next-generation topical therapies for inflammatory skin diseases. Our approach combines rigorous drug engineering, rational prodrug design, and precise dose optimization to deliver therapies that address inflammation at its biological origin—rather than masking downstream symptoms.
At Samdolite, we believe early winners are not defined by where they are today, but by how efficiently and decisively they move forward. We are building first-in-class anti-inflammatory therapies for acne and related dermatologic conditions by targeting the cells that initiate inflammation, rather than chasing secondary inflammatory signals.
A De-Risked Development Stage
Our lead program, CromAzol™, is fully developed at the formulation level. We have completed a successful FDA pre-IND meeting and received clear guidance on the remaining IND-enabling requirements. The path forward is well defined: limited, standard animal safety and pharmacokinetic studies followed by IND submission.
This is execution risk—not discovery risk.
Importantly, all required studies will be conducted through experienced CRO partners. We do not require laboratory build-out, large internal teams, or long exploratory programs. This structure dramatically reduces burn, accelerates timelines, and preserves investor capital for true value-inflection milestones.
Importantly, for topical dermatology products, Phase 1 trials can be conducted directly in acne and/or patients—allowing early efficacy signals alongside safety.
A Scalable Platform, Not a Single Asset
CromAzol™ is the first clinical expression of a broader, modular prodrug platform designed to scale across multiple inflammatory skin diseases, including acne, rosacea, chronic urticaria, atopic dermatitis, psoriasis, and others. The same core architecture can be adapted to new indications with speed and capital efficiency, creating power-law upside rather than single-product exposure.
Capital Efficiency as a Competitive Advantage
Samdolite operates with a deliberately lean model:
• CRO-executed development rather than large in-house teams
• No unnecessary infrastructure or administrative overhead
• Regulatory strategy optimized for accelerated pathways where applicable
Thus, we do not require laboratory build-out, large internal teams, or long exploratory programs. Our business model dramatically reduces burn, accelerates timelines, and preserves investor capital for true value-inflection milestones.This approach allows us to advance faster, spend less, and retain ownership—while maintaining institutional-grade execution standards.
Our Philosophy
We are not here to sell slides or narratives.We are here to ship progress.Every decision at Samdolite is evaluated against one standard: does it accelerate our path to meaningful clinical validation without compromising scientific or regulatory integrity?For investors who value velocity, disciplined execution, and platform-level upside in dermatology and inflammation, Samdolite represents a focused opportunity at a highly asymmetric moment in development.
